114 related articles for article (PubMed ID: 16640659)
1. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
Bjørge L; Stoiber H; Dierich MP; Meri S
Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
[TBL] [Abstract][Full Text] [Related]
2. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
Ravindranath NM; Nishimoto K; Chu K; Shuler C
Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
[TBL] [Abstract][Full Text] [Related]
3. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
Chen S; Caragine T; Cheung NK; Tomlinson S
Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
[TBL] [Abstract][Full Text] [Related]
4. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
6. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
7. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F
Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216
[TBL] [Abstract][Full Text] [Related]
8. Surface expression of complement regulatory proteins, decay-accelerating factor (DAF) and CD59, on cultured human endothelial cells.
Kunii H; Shichishima T; Saitoh Y; Noji H; Maruyama Y
Fukushima J Med Sci; 1998 Dec; 44(2):69-81. PubMed ID: 10091379
[TBL] [Abstract][Full Text] [Related]
9. Complement-regulatory proteins in ovarian malignancies.
Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
[TBL] [Abstract][Full Text] [Related]
10. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
11. Complement as effector system in cancer immunotherapy.
Macor P; Tedesco F
Immunol Lett; 2007 Jul; 111(1):6-13. PubMed ID: 17572509
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of the complement regulatory proteins human DAF and CD59 with an IRES-mediated dicistronic mammalian vector enhances their cell protective effects.
Xu L; Shao H; Wu W; Cao Z; Zhao Z; Liu H; Jiang D; Mao X; Li W
Int J Mol Med; 2005 Sep; 16(3):409-14. PubMed ID: 16077947
[TBL] [Abstract][Full Text] [Related]
13. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
14. Decay accelerating factor (CD55): a target for cancer vaccines?
Spendlove I; Li L; Carmichael J; Durrant LG
Cancer Res; 1999 May; 59(10):2282-6. PubMed ID: 10344729
[TBL] [Abstract][Full Text] [Related]
15. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
16. Increased ovarian tumor cell surface reacting antibodies in patients with ovarian adenocarcinoma after viral oncolysate treatment.
Ioannides CG; Platsoucas CD; Bowen JM; Wharton JT; Freedman RS
Anticancer Res; 1989; 9(1):81-6. PubMed ID: 2705759
[TBL] [Abstract][Full Text] [Related]
17. CD55 is over-expressed in the tumour environment.
Li L; Spendlove I; Morgan J; Durrant LG
Br J Cancer; 2001 Jan; 84(1):80-6. PubMed ID: 11139317
[TBL] [Abstract][Full Text] [Related]
18. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
Zhang X; Feng J; Ye X; Yao Y; Zhou P; Chen X
Gynecol Oncol; 2006 Dec; 103(3):848-52. PubMed ID: 16806435
[TBL] [Abstract][Full Text] [Related]
19. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
20. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
